PT  - JOURNAL ARTICLE
AU  - K Bernstrom
AU  - K Malcolm
AU  - J McGee
AU  - J Maclouf
AU  - S Levy-Toledano
AU  - J R Falck
AU  - F A Fitzpatrick
TI  - 14, 15-cis-episulfide-eicosatrienoic acid, an 'epoxygenase' eicosanoid analog, inhibits ionophore- but not thrombin-induced platelet aggregation.
DP  - 1991 Feb 01
TA  - Molecular Pharmacology
PG  - 114--119
VI  - 39
IP  - 2
4099  - http://molpharm.aspetjournals.org/content/39/2/114.short
4100  - http://molpharm.aspetjournals.org/content/39/2/114.full
SO  - Mol Pharmacol1991 Feb 01; 39
AB  - An 'epoxygenase' eicosanoid analog, 14, 15-cis-episulfide-eicosatrienoic acid, has several unique pharmacological effects on platelets. These include (i) inhibition of ionophore A23187- but not thrombin-induced activation, (ii) inhibition of thromboxane B2 biosynthesis derived from endogenous but not exogenous arachidonic acid, and (iii) attenuation of ionophore-mediated increases in cytosolic Ca2+ when extracellular or membrane Ca2+ is available but not when these pools are excluded. Neither elevation of cyclic AMP levels, a potent inhibitory process, nor direct antagonism of the prostaglandin H2/thromboxane A2 receptor is responsible for the actions of 14, 15-cis-episulfide-eicosatrienoic acid. These properties distinguish 14, 15-cis-episulfide-eicosatrienoic acid from other antiaggregatory substances.